Thousand Oaks, CA-August 5, 2009 Integrated Clinical Solutions (Inclinical) a developer of collaborative clinical operations software for the pharmaceutical, biotechnology and medical device industries, has partnered with Terrosa Technologies (Terrosa) to be its exclusive worldwide sales and distribution agent.
Inclinical and Terrosa have teamed up to bring inclinicalperform, to the clinical trial industry using Software as a Service (SaaS) technology. Terrosa will have exclusive responsibility for the sales of inclinicalperform software as well as developing the go-to-market strategies and sales operations.
Inclinical's, inclinicalperform, provides a collaborative working environment for clinical operations teams comprised of Sponsors, CROs, Sites and other stakeholders. Inclinicalperform provides all the basic functionality of traditional Clinical Trial Management Systems (CTMS) and integrates those functions with collaborative document control and distribution, issue/query resolution and contact resource management. Inclinicalperform is designed to support Title 21 CFR, Part 11, FDA compliance and good Information security practices.
"We are pleased to partner with Integrated Clinical Solutions so that they may maintain their focus on further development of new process automations within inclinicalperform," said Kim Terry, President of Terrosa Technologies. Armerding also stated, "Terrosa's integrated services will allow us to stay focused on what we do best-automating the clinical operations process."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.